Improvement of Duchenne muscular dystrophy phenotype following obestatin treatment
Authors:
Open Access
- 14 September 2018
- journal article
- research article
- Published by Wiley in Journal of Cachexia, Sarcopenia and Muscle
- Vol. 9 (6) , 1063-1078
Abstract
Background This study was performed to test the therapeutic potential of obestatin, an autocrine anabolic factor regulating skeletal muscle repair, to ameliorate the Duchenne muscular dystrophy (DMD) phenotype. Methods and results Using a multidisciplinary approach, we characterized the ageing‐related preproghrelin/GPR39 expression patterns in tibialis anterior (TA) muscles of 4‐, 8‐, and 18‐week‐old mdx mice (n = 3/group) and established the effects of obestatin administration at this level in 8‐week‐old mdx mice (n = 5/group). The findings were extended to in vitro effects on human immortalized DMD myotubes. An analysis of TAs revealed an age‐related loss of preproghrelin expression, as precursor of obestatin, in mdx mice. Administration of obestatin resulted in a significant increase in tetanic specific force (33.0% ± 1.5%, P < 0.05), compared with control mdx mice. Obestatin‐treated TAs were characterized by reduction of fibres with centrally located nuclei (10.0% ± 1.2%, P < 0.05) together with an increase in the number of type I fibres (25.2% ± 1.7%, P < 0.05) associated to histone deacetylases/myocyte enhancer factor‐2 and peroxisome proliferator‐activated receptor‐gamma coactivator 1α axis, and down‐regulation of ubiquitin E3‐ligases by inactivation of FoxO1/4, indexes of muscle atrophy. Obestatin reduced the level of contractile damage and tissue fibrosis. These observations correlated with decline in serum creatine kinase (58.8 ± 15.2, P < 0.05). Obestatin led to stabilization of the sarcolemma by up‐regulation of utrophin, α‐syntrophin, β‐dystroglycan, and α7β1‐integrin proteins. These pathways were also operative in human DMD myotubes. Conclusions These results highlight the potential of obestatin as a peptide therapeutic for preserving muscle integrity in DMD, thus allowing a better efficiency of gene or cell therapy in a combined therapeutic approach.Keywords
Funding Information
- Association Française contre les Myopathies
- European Regional Development Fund (PI15/01537)
- Instituto de Salud Carlos III
This publication has 48 references indexed in Scilit:
- The mdx mouse model as a surrogate forDuchenne muscular dystrophyThe FEBS Journal, 2013
- Rescue of Dystrophic Skeletal Muscle by PGC-1α Involves a Fast to Slow Fiber Type Shift in the mdx MousePLOS ONE, 2012
- Immortalized pathological human myoblasts: towards a universal tool for the study of neuromuscular disordersSkeletal Muscle, 2011
- Current Status of Pharmaceutical and Genetic Therapeutic Approaches to Treat DMDMolecular Therapy, 2011
- Sarcolemmal nNOS anchoring reveals a qualitative difference between dystrophin and utrophinJournal of Cell Science, 2010
- IRES-Mediated Translation of Utrophin A Is Enhanced by Glucocorticoid Treatment in Skeletal Muscle CellsPLOS ONE, 2008
- Histone deacetylase degradation andMEF2 activation promote the formation of slow-twitch myofibersJournal of Clinical Investigation, 2007
- PGC-1α regulates the neuromuscular junction program and ameliorates Duchenne muscular dystrophyGenes & Development, 2007
- Transcriptional co-activator PGC-1α drives the formation of slow-twitch muscle fibresNature, 2002
- Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT MethodMethods, 2001